RTTR - Ritter Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Ritter Pharmaceuticals, Inc.

1880 Century Park East
Suite 1000
Los Angeles, CA 90067
United States

Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. Ira Eliot RitterCo-Founder, Exec. Chairman & Chief Strategic Officer446.06kN/A1949
Mr. Andrew J. RitterCo-Founder, CEO, Pres, Corp. Sec. & Director579.69kN/A1983
Mr. John W. Beck CPA, CPAChief Financial Officer355.07kN/A1960
Ms. Ellen F. MochizukiConsultantN/AN/A1967
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ritter Pharmaceuticals, Inc. develops and sells therapeutic products that modulate the gut microbiome to treat digestive disorders and gastrointestinal diseases. Its lead product candidate is RP-G28, an orally administered galacto-oligosaccharide that is in Phase III clinical trials for the treatment of lactose intolerance. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Corporate Governance

Ritter Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.